REIMAGINE THE WAY YOU TREAT HAE
For your patients, what do you want to reimagine with TAKHZYRO?
Real TAKHZYRO patient
Rethink dosing and administration
One subcutaneous self-injection every 2 weeks1*
*The recommended starting dose is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1
- Significant reduction in mean monthly attacks vs placebo1
- Secondary endpoints of reduction in moderate or severe attacks and attacks requiring acute treatment vs placebo were met1
- There were patients who had zero attacks according to an exploratory analysis1,2
The safety and efficacy of TAKHZYRO were assessed in a 26-week clinical trial of 125 HAE patients ≥12 years of age. The primary efficacy endpoint was the rate of investigator-confirmed attacks during the treatment period compared to placebo. Secondary endpoints included the reduction in moderate or severe attacks and attacks requiring acute treatment. The percentage of patients who had zero attacks over the entire 26-week study duration was a prespecified, exploratory endpoint.1,2
Real TAKHZYRO patient
SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Get patients started
Takeda will provide eligible patients with immediate access to TAKHZYRO at no cost during potential delays in commercial insurance coverage determinations†
†Timing is dependent upon when the forms are received by OnePath®. The Quick Start Program is available to all commercially insured patients ≥12 years of age who are US residents with a confirmed diagnosis of HAE.
Takeda and its affiliates reserve the right to change or discontinue this program at any time, without notice. Void where prohibited by law. This program does not constitute a financial assistance program.
References: 1. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Shire LLC; 2018. 2. Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121.